Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $15.0 million.

  • Cumberland Pharmaceuticals' Shares Outstanding (Weighted Average) rose 616.8% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 616.8%. This contributed to the annual value of $14.1 million for FY2024, which is 166.8% down from last year.
  • Cumberland Pharmaceuticals' Shares Outstanding (Weighted Average) amounted to $15.0 million in Q3 2025, which was up 616.8% from $15.0 million recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $15.0 million during Q2 2021, and registered a low of $14.1 million during Q4 2024.
  • For the 5-year period, Cumberland Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $14.6 million, with its median value being $14.6 million (2022).
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first tumbled by 228.95% in 2022, then surged by 616.8% in 2025.
  • Cumberland Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $14.9 million in 2021, then fell by 2.29% to $14.6 million in 2022, then decreased by 1.82% to $14.3 million in 2023, then decreased by 1.67% to $14.1 million in 2024, then rose by 6.39% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q3 2025, $15.0 million for Q2 2025, and $14.9 million during Q1 2025.